PR Newswire BiotechOriginal article
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
Data ReadoutpositivePMB-CT01Positive
AI Analysis
Summary
PeproMene Bio announced publication of Phase 1 trial results for PMB-CT01, a first-in-class BAFF-R-targeted CAR T-cell therapy, in The Lancet showing deep and durable complete responses in relapsed/refractory B-cell lymphomas, including cases with prior CD19 CAR T-cell failure.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Outcome Details
Phase 1 clinical trial results published in The Lancet demonstrating deep and durable complete responses in relapsed/refractory B-cell lymphomas, including after prior CD19 CAR T-cell failure
Importance:7/10
Sentiment:
0.85
CAR T-cell therapyBAFF-R targetedfirst-in-classlymphomapublicationclinical trialcomplete response
Read the original article
Published by PR Newswire Biotech on September 8, 2026 10:01 AM